We see cancer
differently

We   develop innovative treatments that target GPCR mediated immunosuppression.
By doing so, we unlock groundbreaking clinical outcomes in the battle against cancer.
We recognize the complexity of this disease and advocate a more holistic and patient-centered approach
to overcome the limitations of current treatment methods and bring solutions to patients experiencing therapeutic failure in the clinic.

 

Learn more

Unlocking the power of the immune system

We are steadfast in our commitment to precision research, striving to deliver differentiated and highly effective GPCR-targeting cancer immunotherapies that offer maximum benefit to patients.

Our approach is rooted in a unique understanding of the role of GPCRs in modulating the immune system, the tumor biology, the tumor microenvironment and the immunosuppressive strategies that affect the response to treatment. This profound knowledge is crucial in ensuring optimal clinical development to effectively   fight cancer.

We do not settle for one-size-fits-all solutions. Our priority is to identify the right tumor type, the right patient sub-populations and the right combination treatments. We meticulously position each of our immunotherapies to enhance the efficacy of cancer treatment. This precision in positioning is what sets us apart.

Driving precision medicine
in immuno-oncology

To pave the way for improved immunotherapies, we focus on the development of a robust and clinically relevant biomarker strategy at the early stages of the drug development process to guide our clinical strategy.

We leverage our proprietary cross-validation drug discovery and development platform to identify leading cancer-focused GPCR targets. Our goal is to reverse GPCR-mediated immunosuppression in immuno-oncology. This in-depth expertise, enriched with valuable biomarkers and careful patient selection, allows us to bring differentiated cancer immunotherapies to the clinic and improve patient outcomes.

Learn more

Our growing portfolio
of assets

  Discovery
Candidate
Preclinical
Phase I
Partner
A2aR/A2bR antagonist (M1069) +
Phase I
EP4 receptor antagonist (DT-9081) +
Phase I
Anti-CCR8 antibody (DT-7012) +
Preclinical
PAR2 antagonist (DT-9045) +
Preclinical
Undisclosed GPCR targets +
Discovery
  • Takeda is one of Domain Therapeutics’s partners
  • McGill is one of Domain Therapeutics’s partners
  • Takeda is one of Domain Therapeutics’s partners
  • McGill is one of Domain Therapeutics’s partners
  • Takeda is one of Domain Therapeutics’s partners
  • McGill is one of Domain Therapeutics’s partners